Navigation Links
Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Date:10/25/2007

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients. For many years, corticosteroids have represented the cornerstone of therapy for induction of remission in Inflammatory Bowel Disease (IBD); however, the side-effects emerging with long-term use exceeded the clinical benefits. Recently, Infliximab (IFX) has become an alternative choice in the treatment strategies for CD and UC. Some safety issues are associated with IFX use, mostly related to the development of adverse events (e.g. opportunistic infections, autoimmune disorders and infusion reactions). Major concerns are related to the reactivation of latent tuberculosis and development of malignancy, even if there is no clear evidence the use of IFX increases the incidence of solid cancers. The research published on issue 39 of World Journal of Gastroenterology and led by Renato Caviglia at University Campus Biomedico in Italy aimed to retrospectively evaluate the safety and efficacy of long-term therapy with IFX, reviewing the medical charts of 41 IBD patients who received, after a loading dose of 3 IFX infusions, scheduled retreatment every 8 weeks as maintenance protocol.

Results of this retrospective study confirm current data on the efficacy of IFX in inducing a rapid clinical response in CD and UC, and support the finding, emerging from uncontrolled study data, of prolonged clinical efficacy in maintaining long-lasting remission beyond 1 year of treatment. The steroid-sparing effect of IFX was another important finding emerging from our study, which confirmed the efficacy of a scheduled treatment regimen in avoiding the well-known morbidity associated with long-term corticosteroid therapy. Interestingly, long-term IFX therapy in IBD has been demonstrated to potentially modify the course of the disease. Indeed, 9 out of the 29 CD and 4 out of the 9 UC patients, who discontinued IFX scheduled treatment, were still relapse-free after a median of 16 (range, 5-30) and 6.5 (range, 4-16) months since the last IFX infusion, respectively.

A note of caution is mandatory when considering the possible risk of malignancy associated with the use of anti-TNF-alpha therapy. Further studies on larger scales are needed to further clarify these important aspects.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Rescheduled: Aerial Mosquito Treatment for Philadelphia
2. First Keyhole Heart Valve Surgery Scheduled in Britain
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Thyroid hormone treatment hastens recovery after cardiac surgery
6. Feeding channel created by malaria parasite - a new target for malaria treatments
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Salt Lake City, UT (PRWEB) , ... April 28, 2017 , ... ... that exist in some of their formulas. This begins with the popular ClearLungs Extra ... impacted, they will be changing the formula in the following ways:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to ... of Water, Global Climate Change and Your Health on Voice America sponsored by ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
(Date:4/28/2017)... ... , ... People are starting to accept that hearing aids can be helpful ... stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer ... East region. Côté has 20+ years of experience within the beauty industry, ranging ... with an array of high-end cosmetic brands, retail brands and outlets in Canada ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: